🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

ENVB ENVB

Company Profile ↓
$1.67
-87.90% 1Y
P/E-0.05
52W High$17.40
52W Low$1.27
EPS (TTM)$-36.24

Company Overview

ENVB (ENVB) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue -7.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 3.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:3.36%
1 Year:-7.17%

Stock Price Performance

1 Year:-87.90%
6 Months:-43.39%
3 Months:-52.01%
1 Month:+15.17%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 2% of range
$1.27 $17.40
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)63.86 · Neutral
Price Performance
1M+15.17%
3M-52.01%
6M-43.39%
1Y-87.90%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 90.4% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.05
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
3.36%
Profit 5Y
-
Revenue (YoY)
-7.17%
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
-
ROA
-
Profit Margin
-21.98%
Op Margin
-21.98%
Gross Margin
20.42%
EPS (Latest Qtr)
$-1.08
EPS (TTM)
$-36.24

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
11.67
Debt
-
Total Assets
$5.52M
Current Assets
$5.38M
Working Capital
$4.91M

Ownership

Promoter Holding
10.81%
Chg in Prom Hold
-
FII / Inst Holding
2.93%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$39.91M
EBITDA
-
Free Cash Flow
$-14.10M
Operating Cash Flow
$-8.14M
Shares Outstanding
-
Gross Margin
20.42%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2013Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue -------------------11.02M9.15M-8.25M8.48M----------------
Gross Profit ----1.08M-1.12M982.66K1.44M1.65M1.52M1.70M3.30M2.33M2.56M2.34M2.39M2.35M2.14M2.38M1.90M1.88M1.82M1.89M----------------
Operating Income -4.70K-3.89K-4.56K-7.58K575.17K-3.11K1.08M179.97K-315.76K-981.32K-936.64K-1.29M-630.55K-3.51M-3.95M-1.37M-1.08M6.10M-1.30M-1.48M-1.56M-836.70K-767.51K-489.83K-6.76M-3.36M-3.52M-4.80M-4.71M-5.66M-4.86M-5.76M-3.45M-2.48M-1.90M-2.08M-2.19M-2.52M-1.87M-1.63M
Net Income -4.70K-3.89K-4.56K-7.87K408.37K-3.18K1.08M110.97K-159.55K-1.16M-1.21M-1.78M-721.99K-3.28M-4.07M-1.57M-1.26M5.70M-1.86M-1.26M41.30K-1.10M-818.39K-565.34K-3.25M-908.29K-2.71M-4.52M-2.79M-2.48M-4.68M-6.36M-2.82M-2.46M-1.88M-2.08M-2.18M-2.52M-1.87M-1.63M
Diluted EPS ----0.04-0.110.01-0.02-0.09-0.09-0.13-0.09-0.26-0.31-0.11-0.070.16-1.09-0.67-0.03-0.60-0.48-0.20-----2.73-1.46-2.31-3.04-1.30-9.21-3.72-43.10-14.58-0.97-10.81-1.08
R&D Expense ----------------------50.96K63.30K157.95K879.84K1.22M1.96M2.12M2.06M1.83M2.40M1.28M506.15K565.00K802.72K746.37K1.26M402.42K345.97K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -----36.15M48.59M43.00M39.91M------
Gross Profit -----6.93M10.24M8.98M8.15M------
Operating Income -35.88K-31.39K-22.69K27.21K32.81K-5.38M-10.90M-7.15M-2.30M-5.62M-64.62M-27.42M-16.45M-9.63M-8.77M
Net Income -39.44K-33.38K-24.62K-161-33.64K-2.78M-9.07M-16.90M-2.41M-6.86M-48.98M-18.47M-17.29M-9.57M-8.77M
Diluted EPS ------0.21-0.75-20.47-2.83---13.00-121.29-228.48-36.24
R&D Expense ---------174.08K4.79M8.03M7.25M2.84M2.78M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -1.13K22.45K5.60K4.47K5.08K-39.51M52.20M29.64M108.79K4.10M26.72M19.55M4.30M3.08M5.10M
Total Equity -10.07K-49.52K4.55K-20.07K-20.23K-3.87K258.53K11.66M19.45M-65.45K-1.81M3.42M22.31M14.67M1.96M1.59M4.18M
Cash & Equivalents 1.79K1.13K18.23K1.38K2495.08K1.88M1.38M4.88M1.37M431.40K------
Long Term Debt -------1.54M1.13M0740.34K------
Total Liabilities -------27.84M32.75M18.88M1.92M681.25K4.41M4.00M---
Current Liabilities -50.64K17.89K25.67K24.70K8.96K-12.71M30.37M14.69M14.38M681.25K2.74M4.00M2.34M1.49M918.40K

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -40.67K-30.35K-24.85K-21.63K-43.16K-2.70M-2.74M-2.57M-647.86K-3.89M-11.46M-17.15M-14.09M-7.73M-8.14M
Investing Cash Flow ------6.59M-169.86K-3.64M-284.33K-44.14K2.19M-584.16K11.67K--
Financing Cash Flow 40.00K47.45K8.00K20.50K48.00K8.80M6.41M2.69M560.00K5.53M24.90M18.18M-1.34M7.67M10.58M
Capital Expenditure -----------189.72K-584.16K-5.18K--
Free Cash Flow -----------11.65M-17.73M-14.10M--

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----19.2%21.1%20.9%20.4%------
Operating Margin % ------14.9%-22.4%-16.6%-5.8%------
Net Margin % ------7.7%-18.7%-39.3%-6.0%------
ROE % 79.7%-732.8%122.7%0.8%869.1%-23.8%-46.7%25,815.9%133.1%-201.0%-219.6%-125.9%-883.9%-601.1%-210.0%
ROCE % 72.5%-689.2%113.1%-134.5%-847.6%-20.1%-49.9%-47.8%16.1%-164.5%-269.5%-176.2%-840.8%-604.7%-210.0%

Shareholding Pattern

Insiders
10.81%
Institutions
2.93%
Public Float
3.29%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ENVB

Yahoo Finance Wed, 05 Aug 2026

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

CAMBRIDGE, Mass., August 05, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, toda…

Yahoo Finance ue, 28 Jul 2026

Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

CAMBRIDGE, Mass., July 28, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today …

Yahoo Finance ue, 28 Apr 2026

Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announ…

Yahoo Finance Mon, 23 Feb 2026

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Organigram Secured C$65.2 Million Strategic Investment from British American Tobacco After the Company Agreed to Acquire Sanity Group Canopy Growth Secured Shareholder Backing for MTL Cannabis Acquisition Gree…

Yahoo Finance Fri, 20 Feb 2026

Enveric Biosciences reports EB-003 receptor engagement assay data

Enveric Biosciences (ENVB) announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and ss-arrestin-mediated signaling downstream of the 5-HT2A receptor. Multiple independent, peer-reviewed studies ha…

Yahoo Finance ue, 30 Dec 2025

Enveric Biosciences announces issuance of U.S. patent

Enveric Biosciences (ENVB) announced the issuance of U.S. Patent No. 12,492,179 entitled, “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives” with claims to compositions and methods of treatment for novel molecules with the po…

ENVB — Frequently Asked Questions

What is the current share price of ENVB?

As of 2026-08-05 17:25 PDT, ENVB trades at $1.67 on NASDAQ/NYSE. Its 52-week range is $1.27 to $17.40.

What is the P/E ratio of ENVB?

ENVB trades at a trailing price-to-earnings (P/E) ratio of -0.05.

Is ENVB a good stock to buy?

This page provides a data-driven analysis of ENVB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space